Zoonotic Diseases: A Growing Concern from a Pharmaceutical Perspective

Indu Lata Kanwar, Faculty of Pharmacy, Kalinga University, India
Introduction
Zoonotic diseases – those transmitted from animals to humans – pose a significant global health
threat, with over 60% of emerging infectious diseases originating in animals (Shaheen 2022).
The rise of these diseases has severe implications for public health, as seen with the recent
COVID-19 pandemic. The pharmaceutical industry plays a crucial role in addressing zoonotic
diseases by developing vaccines, therapeutics, and diagnostics, all essential to prevent and
control outbreaks (Ramakrishnan S et al., 2021).
The Role of Pharmaceuticals in Zoonotic Disease Control
Pharmaceuticals are central to managing zoonotic diseases. Key areas of focus include:
Vaccines: Vaccination is the most effective preventive measure against zoonotic diseases
(Carpenter A et al., 2022). Vaccines protect human populations and help control the animal
reservoirs that transmit these diseases. For instance, rabies vaccination is critical for both
humans and animals, while vaccines for livestock like poultry help prevent zoonotic diseases
like avian influenza (Kibenge F et al., 2023).
Antiviral and Antibacterial Medications: The development of antiviral and antibacterial
treatments is crucial for treating infections after they occur (Kalelkar P et al., 2022).
Pharmaceutical companies have responded quickly to outbreaks, as demonstrated by the
development of Tamiflu for influenza and remdesivir for Ebola and COVID-19 (Abd El-Aziz
TM & Stockand JD, 2020).
Diagnostics: Rapid and accurate diagnostics are vital for early detection and containment of
zoonotic diseases (Oeschger TM et al., 2021). Pharmaceutical companies help develop
diagnostic tools, which are crucial in both human and veterinary health. Point-of-care tests for
malaria and dengue, for example, enable early intervention in regions where these diseases are
prevalent (Jain S et al., 2021).
Antimicrobial Resistance (AMR): The rise of antimicrobial resistance complicates the
treatment of zoonotic diseases, as many pathogens evolve resistance to existing antibiotics
(Selvarajan R et al., 2022). The pharmaceutical industry is working to develop new
antimicrobials and alternative therapies, such as bacteriophages, to address this growing
problem.
Notable Zoonotic Diseases and Pharmaceutical Responses
Rabies: Rabies is a deadly viral disease transmitted through animal bites, primarily from dogs.
It is almost always fatal once symptoms appear, but vaccines for both humans and animals have
proven highly effective in preventing its spread (Kumar A et al., 2023).
Ebola: The Ebola virus is transmitted to humans through contact with infected animals, such
as bats or primates (Diakou KI et al., 2023). The pharmaceutical industry responded to the
2014–2016 West African Ebola outbreak by rapidly developing vaccines and antiviral
treatments, including the Ebola vaccine and remdesivir (Torreele E et al., 2023).
COVID-19: The COVID-19 pandemic, caused by SARS-CoV-2, is a zoonotic disease that
likely originated in bats (Al-Salihi KA et al., 2023). The pharmaceutical response to COVID19 was unprecedented, with rapid development and global distribution of vaccines like those
from Pfizer-BioNTech and Moderna. These vaccines have been critical in controlling the
spread of the virus (Buchy P et al., 2021).
Avian Influenza: Avian influenza, or bird flu, is caused by influenza viruses that primarily infect
birds but can sometimes spread to humans (AbuBakar U et al., 2023). Vaccines for poultry and
antiviral medications for humans are key tools in controlling outbreaks. Ongoing research is
essential to prevent new strains of the virus from emerging (Abbas G et al., 2022).
Challenges and Opportunities for the Pharmaceutical Industry
The fight against zoonotic diseases presents several challenges and opportunities for the
pharmaceutical industry:
Vaccine Development: Developing vaccines for zoonotic diseases is complicated by the high
mutation rates of many pathogens (Trovato M et al., 2020). The COVID-19 pandemic
highlighted the importance of flexible vaccine technologies, such as mRNA vaccines, which
can be adapted quickly to new threats (Tsakiri M et al., 2021; Fang E et al., 2022).
Antimicrobial Resistance: The rise of drug-resistant zoonotic pathogens demands innovative
approaches to developing new antibiotics and alternative treatments (Muteeb G et al., 2023).
Pharmaceutical companies are exploring bacteriophage therapy and other novel solutions to
address the growing threat of antimicrobial resistance (Kaur R et al., 2022).
Collaborative Efforts: Tackling zoonotic diseases requires collaboration between
pharmaceutical companies, governments, international health organizations, and the veterinary
sector (Sharam M et al., 2023). The “One Health” approach integrates human, animal, and
environmental health, is crucial for preventing and controlling zoonotic disease outbreaks
(Singh S et al., 2024).
Conclusion
Zoonotic diseases are a growing threat to global health, driven by human activities such as
deforestation, intensive farming, and wildlife trade. The pharmaceutical industry is pivotal in
preventing and treating these diseases through vaccines, diagnostics, and therapeutic
development. As the threat of zoonotic diseases continues to rise, pharmaceutical companies
must invest in innovative solutions to safeguard both human and animal health and prevent
future outbreaks.
References
1. Shaheen MN. The concept of one health applied to the problem of zoonotic diseases.
Reviews in medical virology. 2022 Jul;32(4):e2326.
2. Ramakrishnan SG, Robert B, Salim A, Ananthan P, Sivaramakrishnan M, Subramaniam
S, Natesan S, Suresh R, Rajeshkumar G, Maran JP, Al-Dhabi NA. Nanotechnology
based solutions to combat zoonotic viruses with special attention to SARS, MERS, and
COVID 19: Detection, protection and medication. Microbial pathogenesis. 2021 Oct
1;159:105133.
3. Carpenter A, Waltenburg MA, Hall A, Kile J, Killerby M, Knust B, Negron M, Nichols
M, Wallace RM, Behravesh CB, McQuiston JH. Vaccine preventable zoonotic diseases:
challenges and opportunities for public health progress. Vaccines. 2022 Jun
22;10(7):993.
4. Kibenge FS. A One Health approach to mitigate the impact of influenza A virus (IAV)
reverse zoonosis is by vaccinating humans and susceptible farmed and pet animals.
American Journal of Veterinary Research. 2023 Jun 1;84(6).
5. Kalelkar PP, Riddick M, García AJ. Biomaterial-based antimicrobial therapies for the
treatment of bacterial infections. Nature Reviews Materials. 2022 Jan;7(1):39-54.
6. Abd El-Aziz TM, Stockand JD. Recent progress and challenges in drug development
against COVID-19 coronavirus (SARS-CoV-2)-an update on the status. Infection,
Genetics and evolution. 2020 Sep 1;83:104327.
7. Oeschger TM, McCloskey DS, Buchmann RM, Choubal AM, Boza JM, Mehta S,
Erickson D. Early warning diagnostics for emerging infectious diseases in developing
into late-stage pandemics. Accounts of Chemical Research. 2021 Sep 15;54(19):3656-
66.
8. Jain S, Nehra M, Kumar R, Dilbaghi N, Hu T, Kumar S, Kaushik A, Li CZ. Internet of
medical things (IoMT)-integrated biosensors for point-of-care testing of infectious
diseases. Biosensors and Bioelectronics. 2021 May 1;179:113074.
9. Selvarajan R, Obize C, Sibanda T, Abia AL, Long H. Evolution and emergence of
antibiotic resistance in given ecosystems: possible strategies for addressing the
challenge of antibiotic resistance. Antibiotics. 2022 Dec 24;12(1):28.
10. Kumar A, Bhatt S, Kumar A, Rana T. Canine rabies: an epidemiological significance,
pathogenesis, diagnosis, prevention, and public health issues. Comparative
Immunology, Microbiology and Infectious Diseases. 2023 Jun 1;97:101992.
11. Diakou KI, Mitsis T, Pierouli K, Papakonstantinou E, Bongcam-Rudloff E, Wayengera
M, Vlachakis D. Ebola virus disease and current therapeutic strategies: a review.
GeNeDis 2020: Genetics and Neurodegenerative Diseases. 2021:131-7.
12. Torreele E, Boum Y, Adjaho I, Alé FG, Issoufou SH, Harczi G, Okonta C, Olliaro P.
Breakthrough treatments for Ebola virus disease, but no access—what went wrong, and
how can we do better?. The Lancet Infectious Diseases. 2023 Jul 1;23(7):e253-8.
13. Al-Salihi KA, Khalaf JM. The emerging SARS-CoV, MERS-CoV, and SARS-CoV-2:
An insight into the viruses zoonotic aspects. Veterinary world. 2021 Jan;14(1):190.
14. Buchy P, Buisson Y, Cintra O, Dwyer DE, Nissen M, de Lejarazu RO, Petersen E.
COVID-19 pandemic: lessons learned from more than a century of pandemics and
current vaccine development for pandemic control. International Journal of Infectious
Diseases. 2021 Nov 1;112:300-17.
15. AbuBakar U, Amrani L, Kamarulzaman FA, Karsani SA, Hassandarvish P, Khairat JE.
Avian influenza virus tropism in humans. Viruses. 2023 Mar 24;15(4):833.
16. Abbas G, Yu J, Li G. Novel and alternative therapeutic strategies for controlling avian
viral infectious diseases: Focus on infectious bronchitis and avian influenza. Frontiers
in Veterinary Science. 2022 Jul 22;9:933274.
17. Trovato M, Sartorius R, D’Apice L, Manco R, De Berardinis P. Viral emerging diseases:
challenges in developing vaccination strategies. Frontiers in immunology. 2020 Sep
3;11:2130.
18. Tsakiri M, Naziris N, Demetzos C. Innovative vaccine platforms against infectious
diseases: Under the scope of the COVID-19 pandemic. International Journal of
Pharmaceutics. 2021 Dec 15;610:121212.
19. Fang E, Liu X, Li M, Zhang Z, Song L, Zhu B, Wu X, Liu J, Zhao D, Li Y. Advances
in COVID-19 mRNA vaccine development. Signal transduction and targeted therapy.
2022 Mar 23;7(1):94.
20. Muteeb G, Rehman MT, Shahwan M, Aatif M. Origin of antibiotics and antibiotic
resistance, and their impacts on drug development: A narrative review.
Pharmaceuticals. 2023 Nov 15;16(11):1615.
21. Kaur R, Sethi N. Phage therapy as an alternative treatment in the fight against AMR:
Real-world problems and possible futures. InEmerging modalities in mitigation of
antimicrobial resistance 2022 Jan 31 (pp. 357-374). Cham: Springer International
Publishing.
22. Sharan M, Vijay D, Yadav JP, Bedi JS, Dhaka P. Surveillance and response strategies
for zoonotic diseases: A comprehensive review. Science in One Health. 2023 Nov
1:100050.
23. Singh S, Sharma P, Pal N, Sarma DK, Tiwari R, Kumar M. Holistic one health
surveillance framework: synergizing environmental, animal, and human determinants
for enhanced infectious disease management. ACS Infectious Diseases. 2024 Feb
28;10(3):808-26